Pfizer discontinues Ph III trial of Sutent in advanced liver cancer as it fails versus Bayer's Nexavar
In another setback to extend the indications of its cancer drug Sutent (sunitinib), global drug behemoth Pfizer has announced the discontinuation of the SUN 1170 Phase III open-label study of the compound in advanced hepatocellular carcinoma (HCC), or liver cancer.
Only last month the company revealed that two Phase III studies of Sutent - which generated sales of $964 million in its current indication last year ' in advanced breast cancer did not meet their primary endpoints (The Pharma Letter March 12).
Sutent also failed to achieve positive results in tests against Roche's Xeloda (capecitabine) in breast cancer and Avastin (bevacizumab) in combination with Bristol-Myers Squibb's Taxol (paclitaxel)and versus placebo in combination with Sanofi-Aventis' Taxotere (docetaxel), as well as another testing it when combined with Xeloda.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze